Financials CareDx, Inc

Equities

CDNA

US14167L1035

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
7.56 USD 0.00% Intraday chart for CareDx, Inc -9.03% -37.00%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 915.3 3,569 2,401 610.9 649.2 391.4 - -
Enterprise Value (EV) 1 915.3 3,569 2,053 317.8 413.8 367 392.5 392.4
P/E ratio -41.5 x -181 x -77.1 x -7.92 x -3.39 x -5.02 x -6.42 x -
Yield - - - - - - - -
Capitalization / Revenue 7.2 x 18.6 x 8.1 x 1.9 x 2.32 x 1.47 x 1.37 x 1.24 x
EV / Revenue 7.2 x 18.6 x 6.93 x 0.99 x 1.48 x 1.37 x 1.37 x 1.25 x
EV / EBITDA 220 x 448 x 115 x -18.1 x -10.9 x -13.5 x -67.4 x 22.1 x
EV / FCF -184,174,060 x - - - - - - -
FCF Yield -0% - - - - - - -
Price to Book - - - 1.42 x - - - -
Nbr of stocks (in thousands) 42,436 49,257 52,802 53,537 54,098 51,779 - -
Reference price 2 21.57 72.45 45.48 11.41 12.00 7.560 7.560 7.560
Announcement Date 2/27/20 2/24/21 2/24/22 2/27/23 2/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 127.1 192.2 296.4 321.8 280.3 267 286.6 314.7
EBITDA 1 4.164 7.962 17.83 -17.54 -37.98 -27.18 -5.823 17.72
EBIT 1 -24.53 -22.53 -29.73 -77.23 -203.4 -92.68 -74.97 -
Operating Margin -19.31% -11.72% -10.03% -24% -72.55% -34.71% -26.16% -
Earnings before Tax (EBT) 1 -23.95 -19.75 -32.09 -76.23 -190.1 -80.51 -64.21 -
Net income 1 -21.97 -18.71 -30.66 -76.61 -190.3 -80.4 -64.05 -
Net margin -17.29% -9.74% -10.34% -23.81% -67.88% -30.11% -22.35% -
EPS 2 -0.5200 -0.4000 -0.5900 -1.440 -3.540 -1.505 -1.177 -
Free Cash Flow -4.97 - - - - - - -
FCF margin -3.91% - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 2/27/20 2/24/21 2/24/22 2/27/23 2/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 75.59 79.22 79.42 80.63 79.36 82.38 77.26 70.3 67.19 65.57 63.25 65.43 68.83 69.52 68.65
EBITDA 1 4.697 -1.358 -5.649 -5.733 -2.476 -3.676 -6.415 -10.35 -10.95 -10.27 -11.85 -7.391 -4.696 -3.65 -4.63
EBIT 1 -8.727 -15.4 -19.05 -21.72 -17.34 -19.12 -24.32 -27.62 -28.78 -122.6 -27.91 -24.05 -20.66 -20.04 -22.6
Operating Margin -11.55% -19.44% -23.99% -26.94% -21.85% -23.21% -31.48% -39.29% -42.84% -187.03% -44.12% -36.76% -30.02% -28.82% -32.91%
Earnings before Tax (EBT) 1 -12.06 -17.05 -19.66 -21.75 -16.67 -18.16 -23.62 -25.02 -23.56 -117.9 -24.39 -20.96 -17.63 -17.18 -19.84
Net income 1 -11.9 -16.15 -19.65 -21.7 -16.94 -18.33 -23.75 -24.95 -23.48 -118.1 -24.68 -20.94 -17.61 -17.15 -19.8
Net margin -15.74% -20.39% -24.74% -26.91% -21.34% -22.25% -30.74% -35.49% -34.95% -180.11% -39.02% -32% -25.58% -24.67% -28.84%
EPS 2 -0.2300 -0.3100 -0.3700 -0.4100 -0.3200 -0.3400 -0.4400 -0.4600 -0.4300 -2.210 -0.4650 -0.3925 -0.3275 -0.3200 -0.3667
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 10/28/21 2/24/22 5/5/22 8/4/22 11/3/22 2/27/23 5/10/23 8/8/23 11/8/23 2/28/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - 1.1 0.99
Net Cash position 1 - - 348 293 235 24.5 - -
Leverage (Debt/EBITDA) - - - - - - -0.1894 x 0.0558 x
Free Cash Flow -4.97 - - - - - - -
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - 8.050 - - - -
Cash Flow per Share - - - - - - - -
Capex 2.2 - - - - - - -
Capex / Sales 1.73% - - - - - - -
Announcement Date 2/27/20 2/24/21 2/24/22 2/27/23 2/28/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
7.56 USD
Average target price
12.5 USD
Spread / Average Target
+65.34%
Consensus
  1. Stock Market
  2. Equities
  3. CDNA Stock
  4. Financials CareDx, Inc